Ibrutinib (PCI-32765)

For research use only. Not for use in humans.

製品コードS2680

Ibrutinib (PCI-32765)化学構造

CAS No. 936563-96-1

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.

サイズ 価格(税別)  
10mM (1mL in DMSO) JPY 47100
JPY 30200
JPY 163000
JPY 412000
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(463)

製品安全説明書

Target Protein Ligand阻害剤の選択性比較

生物活性

製品説明 Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.
ターゲット
BTK [1]
(Cell-free assay)
BLK [1]
(Cell-free assay)
Bmx [1]
(Cell-free assay)
CSK [1]
(Cell-free assay)
FGR [1]
(Cell-free assay)
0.5 nM 0.5 nM 0.8 nM 2.3 nM 2.3 nM
体外試験

Ibrutinib shows the potent and irreversible inhibitory effect and selectivity for Btk enzymatic activity. In BCR pathway-activated DOHH2 cell line, Ibrutinib inhibits autophosphorylation of Btk, phosphorylation of Btk's physiological substrate PLCγ, and phosphorylation of further downstream kinase, ERK with IC50 of 11 nM, 29 nM and 13 nM, respectively. [1] Ibrutinib exhibits a significant dose-dependent and time-dependent induction of cytotoxicity in chronic lymphocytic leukemia (CLL) cells. In addition, Ibrutinib induces cell death depending on caspase pathway activation and antagonizes the ability of CLL cells to proliferate after TLR signaling. [2] A recent study shows that Ibrutinib inhibits BCR-activated primary B cell proliferation with IC50 of 8 nM and results in inhibition of TNFα, IL-1β and IL-6 production in primary monocytes with IC50 of 2.6 nM, 0.5 nM and 3.9 nM, respectively. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human Rec1 cells NEfwUYJHfW6ldHnvckBie3OjeR?= MnvWNk42KM7:TR?= NGfQT5Q3KGh? M{fudWlvcGmkaYTpc44hd2ZiTInuJJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDS[YMyKGOnbHzzJIF1KDJwNTD1UUBqdmO3YnH0[YQh\m:{IE[gbJJ{KGK7IGfld5Rmem5iYnzveJRqdmdibXX0bI9l MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ{Mki3O{c,OjV{MkK4O|c9N2F-
human WSU-NHL cells M3;oVmN6fG:2b4jpZ:Kh[XO|YYm= MVG3NkBp MlzlR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gW3NWNU6KTDDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4VvfCClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkC5JO69VQ>? MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUK5NUc,OjR7MUWyPVE9N2F-
human SU-DHL6 cells MULDfZRwfG:6aXRCpIF{e2G7 MmTtO|IhcA>? MYnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTWU1FUEx4IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIx2dWmwZYPj[Y51KGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwNUig{txONg>? NGW2e3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVI6OSd-MkS5NVUzQTF:L3G+
human DOHH2 cells M3nnN2N6fG:2b4jpZ:Kh[XO|YYm= NE\Fbm04OiCq MonjR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSG9JUDJiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gcJVucW6nc3PlcpQh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC52MTFOwG0v Ml7BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUWyPVEoRjJ2OUG1NlkyRC:jPh?=
Sf9 cells NIXEZndHfW6ldHnvckBie3OjeR?= NVLoUlZCOSCq NHnOOYtKdmirYnn0bY9vKG:oIFzZUk1CKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgZYZ1\XJiNkCgcYlveyCkeTDUVk1HWkWWIFHzd4F6NCCLQ{WwQVAvOiEQvF2u MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl3OEW0O{c,OjF7NUi1OFc9N2F-
human Ramos cells Mn\oSpVv[3Srb36gZZN{[Xl? M2\jZ|EhcA>? M1LpdmlvcGmkaYTpc44hd2ZiQoTrJIlvKGi3bXHuJHJidW:|IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhWEyFLXfhcY1iOiCyaH;zdIhwenmuYYTpc44h[XRiVInyNVIyPyCjZoTldkAyKGi{IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqeyxiSVO1NF0yPCCwTT6= MmX2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUWyPVEoRjJ2OUG1NlkyRC:jPh?=
human Pfeiffer cells NGLBZ3dHfW6ldHnvckBie3OjeR?= NVKy[oZuPzJiaB?= NH:0SZBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBR\mWrZn\ldkBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCudX3pcoV{[2WwdDDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yJI5ONg>? NFi0OFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVI6OSd-MkS5NVUzQTF:L3G+
Sf9 cells NUHQdJl7TnWwY4Tpc44h[XO|YYm= NV21OIJTOSCq NHzFdGlKdmirYnn0bY9vKG:oIHj1cYFvKG[3bHytcIVv\3SqIFLUT{BmgHC{ZYPz[YQhcW5iU3[5JINmdGy|IIXzbY5oKE[DTT3TdoN1cWSnIIDldJRq\GViYYOgd5Vje3S{YYTlJIFnfGW{IE[wJI1qdnNiYomgWHIuTlKHVDDBd5Nige,:jDDJR|UxRTBwNTDuUU4> M2rLVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUW4OVQ4Lz5{MUm1PFU1PzxxYU6=
Sf9 insect cells M13YN2Z2dmO2aX;uJIF{e2G7 NGXnVGk3OCCvaX7z MknhTWM2OCB;IECuNFAxOyEQvF2= M{Hr[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUS2NVM3Lz5{OUG0OlE{PjxxYU6=
sf9 cells MkC1SpVv[3Srb36gZZN{[Xl? MlzvTWM2OCB;IECuNFAxOyEQvF2= NVXXVYNCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5PVQ4OzZpPkK3PVk1PzN4PD;hQi=>
Sf9 insect cells NYLBeHVlTnWwY4Tpc44h[XO|YYm= M3PkVVYxKG2rboO= NHz6Wo9KSzVyIE2gNE4xODB|NDFOwG0> M374bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUGyNVc2Lz5{N{mxNlE4PTxxYU6=
Sf9 insect cells MYfGeY5kfGmxbjDhd5NigQ>? MljNOlAhdWmwcx?= MknGTWM2OCB;IECuNFAxOzRizszN NGi5XII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESzNlk1Pid-Mki0N|I6PDZ:L3G+
Sf9 insect cells MnnOSpVv[3Srb36gZZN{[Xl? NGjGNWI3OCCvaX7z MV3JR|UxKD1iMD6wNFA{PCEQvF2= NVzFT2tURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5OVYxOzdpPkK3PVU3ODN5PD;hQi=>
Sf9 cells M{GwfWZ2dmO2aX;uJIF{e2G7 NH3kNoM3OCCvaX7z NFfQdlhKSzVyIE2gNE4xODB2IN88US=> NXj5SVI{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwNFYyPDNpPkOwNFA3OTR|PD;hQi=>
Sf9 cells NHX2ZXhHfW6ldHnvckBie3OjeR?= NUfvbWhJPjBibXnudy=> NH64NJRKSzVyIE2gNE4xODB3IN88US=> M1fmOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUW4OVQ4Lz5{MUm1PFU1PzxxYU6=
Ramos cells MV;GeY5kfGmxbjDhd5NigQ>? NVnQZpA4OSCq NXnLOFFPUUN3MDC9JFAvODByNTFOwG0> NUTjfYdwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFAzPjFpPkK4NlgxOjZzPD;hQi=>
Sf9 cells NFXSenFHfW6ldHnvckBie3OjeR?= Mnv3OlAhdWmwcx?= M{DBe2lEPTBiPTCwMlAxOSEQvF2= NH:ybJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEC3O|YxQCd-M{CwO|c3ODh:L3G+
Pfeiffer cells M2PSdGN6fG:2b4jpZ4l1gSCjc4PhfS=> NWnI[WtnPzJiaB?= MVjHTVUxKD1iMD6wNFIh|ryP MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUK5NUc,OjR7MUWyPVE9N2F-
B cells MV;GeY5kfGmxbjDhd5NigQ>? M4OyZVEhcA>? NV34OlhwUUN3MDC9JFAvODB2NjFOwG0> NW\tTXI{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyPVA6QDhpPkOwNlkxQTh6PD;hQi=>
Sf9 insect cells M2mzfGZ2dmO2aX;uJIF{e2G7 NGC2[VczKHSxIE[wJI1qdnN? MVfLbUA:KDBwMEC0PEDPxE1? NEfydYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
Ramos cells NYf6b25MTnWwY4Tpc44h[XO|YYm= MUKxJIg> MlzPTWM2OCB;IECuNFA4PSEQvF2= NEDG[IY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVI6OSd-MkS5NVUzQTF:L3G+
Sf9 insect cells MYDGeY5kfGmxbjDhd5NigQ>? MXy2NEBucW6| M{HIfmlEPTBiPTCwMlAxQCEQvF2= NGDhPHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
TMD8 cells NWK5epdTSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NGnpZos4OiCq NH:1e4ZKSzVyIE2gNE4xOSEQvF2= M{HSUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{G1NFI{Lz5{OUexOVAzOzxxYU6=
CD19+ B cells NYPxcGl3TnWwY4Tpc44h[XO|YYm= NFzpUW0yKGh? MWLJR|UxKD1iMD6wNVIh|ryP NHK5XZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS1O|k5Oid-Mkm0OVc6QDJ:L3G+
Sf9 insect cells MWDGeY5kfGmxbjDhd5NigQ>? NY\CVHpVPjBibXnudy=> NXXlOWFnUUN3MDC9JFAvODF{IN88US=> MoDkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
Ramos cells NIjHS45HfW6ldHnvckBie3OjeR?= MnHuNUBp NHXuWpFKSzVyIE2gNE4xOTRizszN NH;JZmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVI6OSd-MkS5NVUzQTF:L3G+
Sf9 insect cells M4XkO2Z2dmO2aX;uJIF{e2G7 MljCNUBp MoC3TWM2OCB;IECuNFE1PCEQvF2= NHfyVHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUexOVAzOyd-Mkm3NVUxOjN:L3G+
Sf9 insect cells MnW1SpVv[3Srb36gZZN{[Xl? MWi2NEBucW6| M{nuWWlEPTBiPTCwMlAyPjFizszN MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF2NkGzOkc,OjlzNE[xN|Y9N2F-
HCC827 cells NXPnZWxKSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MWW3NkBp NU\QXY5WUUN3MDC9JFAvODN7IN88US=> NYfDfmdmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3N|Q2QDFpPkK4O|M1PThzPD;hQi=>
PC9 cells M3;W[GZ2dmO2aX;uJIF{e2G7 MXG3NkBp NX;oOINJT0l3MDC9JFAvODVizszN MoDaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
Sf9 cells NX7sSGRITnWwY4Tpc44h[XO|YYm= NX;xOZdvPjBibXnudy=> MkL3TWM2OCB;IECuNUDPxE1? NWmyem5VRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwNFYyPDNpPkOwNFA3OTR|PD;hQi=>
H3255 cells MmPZSpVv[3Srb36gZZN{[Xl? NHW5N2Y4OiCq Mn7XS2k2OCB;IECuNVEh|ryP NEPkd3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
BaF3 cells NIf1Xo5HfW6ldHnvckBie3OjeR?= MnH4O|IhcA>? NULQT2NuT0l3MDC9JFAvOTJizszN M1nZcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkOwOVU{Lz5{Nk[zNFU2OzxxYU6=
BAF3 cells NHj0dlFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NHX5PWU4OiCq MmPSS2k2OCB;IECuNVIh|ryP NIfHNYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
Sf9 insect cells MUPGeY5kfGmxbjDhd5NigQ>? M{nzfFYxKG2rboO= NWq0boFpUUN3MDC9JFAvOTJ|IN88US=> NHjYemc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
Sf9 insect cells MVrGeY5kfGmxbjDhd5NigQ>? M{LQWlYxKG2rboO= NVOxUFJoUUN3MDC9JFAvOTR4IN88US=> M{LmU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
BAF3 cells MlrSSpVv[3Srb36gZZN{[Xl? MnHhO|IhcA>? NHnJcFlIUTVyIE2gNE4yPiEQvF2= NISyOWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
Sf9 cells MY\GeY5kfGmxbjDhd5NigQ>? MUi2NEBucW6| MXvJR|UxKD1iMD6yJO69VQ>? MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl3OEW0O{c,OjF7NUi1OFc9N2F-
MV411 cells NHPYcHVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWDieZl3T0l3MDC9JFAvOjVizszN MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh|MUW1PVc9N2F-
MV4-11 cells NYTjXlJSSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MlnhO|IhcA>? NXLJb2tIT0l3MDC9JFAvOzNizszN MnfCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4M{C1OVMoRjJ4NkOwOVU{RC:jPh?=
MV4-11 cells M2rpSmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 M{TuS|czKGh? NIjiW|dIUTVyIE2gNE4{OyEQvF2= MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
DOHH2 cells NXjNbWNCS3m2b4TvfIlkcXS7IHHzd4F6 MlHNO|IhcA>? MlKwS2k2OCB;IECuOFEh|ryP M1zFWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUG1NlkyLz5{NEmxOVI6OTxxYU6=
HCC827 cells NF;jOpFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= M1XUd|k3KGh? M{[1XGVEPTBiPTCwMlQ2KM7:TR?= Mmi4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUO1O|UoRjJ6OEWzOVc2RC:jPh?=
SU-DHL6 cells NUnENIJFS3m2b4TvfIlkcXS7IHHzd4F6 M3TOT|czKGh? NWr6PFNpT0l3MDC9JFAvPThizszN NGj4eGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVI6OSd-MkS5NVUzQTF:L3G+
M07e cells NEL5blJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYfwcll5T0l3MDC9JFAvPTlizszN NV3Oem1yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N|E2PTl5PD;hQi=>
NCI-H1975 cells MW\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? MmPGPVYhcA>? NUTXbnVlTUN3MDC9JFAvPjRizszN NXmzUZp[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OVM2PzVpPkK4PFU{PTd3PD;hQi=>
SU-DHL-2 cells Mn\5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH3J[VFIUTVyIE2gNE43PCEQvF2= MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh|MUW1PVc9N2F-
HEK293T cells M3XjOGZ2dmO2aX;uJIF{e2G7 MXSxJIg> NFrMSIdKSzVyIE2gNE46KM7:TR?= M3i1VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiwNlYyLz5{OEK4NFI3OTxxYU6=
Ramos cells M3uycmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MkToO|IhcA>? MXfJR|UxKD1iMD65NkDPxE1? Mnm5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5MUWwNlMoRjJ7N{G1NFI{RC:jPh?=
BA/F3 cells MWHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? NVK2cVZlPzJiaB?= NYTw[IJZUUN3MDC9JFEh|ryP MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ3OEWyNUc,OjZ{NUi1NlE9N2F-
WSU-NHL cells M2jpXGN6fG:2b4jpZ4l1gSCjc4PhfS=> M1js[FczKGh? NVv1eJZxT0l3MDC9JFEvODlizszN M3fm[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUG1NlkyLz5{NEmxOVI6OTxxYU6=
NCI-H1975 cells NGXs[GlHfW6ldHnvckBie3OjeR?= M1[yVlczKGh? MVnHTVUxKD1iMT6yJO69VQ>? MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
NCI-H1975 cells NIHMS4FCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= M{TO[lczKGh? Ml\FTWM2OCB;IEGuNlch|ryP NIK0PVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEezOFU5OSd-Mki3N|Q2QDF:L3G+
Raji cells MYnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? MWW0PEBp MmW4TWM2OCB;IEGuOFkh|ryP Mn7YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3NkeyPVUoRjJ7NU[3Nlk2RC:jPh?=
Pfeiffer cells MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHnxTpVIUTVyIE2gNU43KM7:TR?= MlnNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
A431 cells MnTYRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? MU[5OkBp NYHKdos2TUN3MDC9JFIvOzhizszN MlnSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUO1O|UoRjJ6OEWzOVc2RC:jPh?=
BAF3 cells Mn7URY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NYjMXGM4PzJiaB?= MmrPS2k2OCB;IEKuOUDPxE1? MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
U937 cells NHXFbYRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGPKclRIUTVyIE2gNk46KM7:TR?= NUK4eYx1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N|E2PTl5PD;hQi=>
NB4 cells MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIXMfpZIUTVyIE2gN{DPxE1? NFnjS|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
Ramos cells NWjMd5ZuT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYOyPFE3T0l3MDC9JFMvPCEQvF2= M1X0O|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
SKM1 cells M1\u[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXjHTVUxKD1iMz62JO69VQ>? NHrOUow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
U2932 cells NHm4VoNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoHIS2k2OCB;IESuOEDPxE1? MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh|MUW1PVc9N2F-
Ramos cells MlPQRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? M1LFXVczKGh? NUL4ToVnUUN3MDC9JFUvOTRizszN Mk\sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByME[xOFMoRjNyMEC2NVQ{RC:jPh?=
Ramos cells MkHCRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? Ml;2OFghcA>? NF7sUppKSzVyIE2gOU4yPCEQvF2= MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl3NkCzO{c,Ojd7NU[wN|c9N2F-
Ramos cells Mnj4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NGHBfYg1QCCq M4HjZmlEPTBiPTC1Mlg5KM7:TR?= MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR|Mkm0Okc,Ojh2M{K5OFY9N2F-
Ramos cells NX\lXXBlSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NUPqXGx3PzJiaB?= MWnJR|UxKD1iNj62NkDPxE1? MnXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzNE[xN|YoRjJ7MUS2NVM3RC:jPh?=
K562 cells MkLNRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? MoXZOFghcA>? NX23NGkyUUN3MDC9JFcvPSEQvF2= MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB5N{[wPEc,OzByN{e2NFg9N2F-
HL60 cells MlT3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NYPWTGhtPDhiaB?= NW\lUGlrUUN3MDC9JFgh|ryP M37TSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEe3OlA5Lz5|MEC3O|YxQDxxYU6=
Ramos cells NUjSPGtSSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= M1\JUVQ5KGh? MVXJR|UxKD1iOD6xNUDPxE1? NX\ieGtGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5PVQ4OzZpPkK3PVk1PzN4PD;hQi=>
Ramos cells MXHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? MUC0PEBp M2Hj[GlEPTBiPTC4MlI3KM7:TR?= M3PBcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NU[3Nlk2Lz5{OUW2O|I6PTxxYU6=
OCI-AML3 cells NV[5[GhGT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYDHTVUxKD1iOT6yJO69VQ>? MoPLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
BAF3 cells NYLudZMzS3m2b4TvfIlkcXS7IHHzd4F6 M2H4UVczKGh? MWnHTVUxKD1iMUCg{txO NXvvOnkxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2N|A2PTNpPkK2OlMxPTV|PD;hQi=>
BAF3 cells NYqzOW9nSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NGOwbWY4OiCq NVm1bHFzT0l3MDC9JFExKM7:TR?= MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
BAF3 cells NX7GVZNpT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1fad|czKGh? MnfXS2k2OCB;IEGwJO69VQ>? M1nlN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
NAMALWA cells NX7iOmRkSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= M1vh[VczKGh? NIS1[WpKSzVyIE2gNVAvPDVizszN MoHaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzNE[xN|YoRjJ7MUS2NVM3RC:jPh?=
Ramos cells NGHsd4xCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= M1nNbVQ5KGh? MmHyTWM2OCB;IEGyMlYh|ryP MoOzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7MUKxO|UoRjJ5OUGyNVc2RC:jPh?=
Raji cells M321NGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MoHWOFghcA>? NGX6c5pKSzVyIE2gNVQvOiEQvF2= NGO1R4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEC3O|YxQCd-M{CwO|c3ODh:L3G+
Raji cells MWrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? MkPHOFghcA>? MYLJR|UxKD1iMUWuNkDPxE1? M1jwT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUm0O|M3Lz5{N{m5OFc{PjxxYU6=
MIAPaCa2 cells NW\zXIE2S3m2b4TvfIlkcXS7IHHzd4F6 MYezJIRigXN? MkTETWM2OCB;IEG2MlYh|ryP MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB5N{KyPEc,OjdyN{eyNlg9N2F-
HeLa cells MXjDfZRwfG:6aXPpeJkh[XO|YYm= NWXpT3ZUOyCmYYnz NETnbGtKSzVyIE2gNVYvQCEQvF2= NYr6dW15RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewO|czOjhpPkK3NFc4OjJ6PD;hQi=>
Raji cells MV3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? NILFTng1QCCq MkXQTWM2OCB;IEG5MlMh|ryP NEfTRYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{mxNlE4PSd-Mke5NVIyPzV:L3G+
Raji cells NGj2[3lCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= Mo[xOFghcA>? NW\rWnplUUN3MDC9JFE6NjNizszN MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR|Mkm0Okc,Ojh2M{K5OFY9N2F-
Raji cells M1jieWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 M1frVVczKGh? MmXDTWM2OCB;IEG5MlUh|ryP NUDwdoh5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwNFYyPDNpPkOwNFA3OTR|PD;hQi=>
Raji cells Mo\wRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NHjBPIc1QCCq MlThTWM2OCB;IEG5MlUh|ryP MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl3NkCzO{c,Ojd7NU[wN|c9N2F-
NAMALWA cells NXXCUmg3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= Mn\0O|IhcA>? MYDJR|UxKD1iMUmuOkDPxE1? MmnqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByME[xOFMoRjNyMEC2NVQ{RC:jPh?=
A2780 cells M3TzbWN6fG:2b4jpZ4l1gSCjc4PhfS=> MVizJIRigXN? MUfFR|UxKD1iMkCuNUDPxE1? NUnR[FU3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewO|czOjhpPkK3NFc4OjJ6PD;hQi=>
Raji cells NXnsXpBsSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MkK3O|IhcA>? NF3RUJpKSzVyIE2gNlAvQDhizszN MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF2NkGzOkc,OjlzNE[xN|Y9N2F-
A549 cells NVTI[YQ6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NXXXflZ[PzJiaB?= MVzJR|UxKD1iMkGuO|kh|ryP MknqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5M{S1PFEoRjJ6N{O0OVgyRC:jPh?=
SW480 cells MorYR5l1d3SxeHnjbZR6KGG|c3H5 MUKzJIRigXN? M3X2XGlEPTBiPTCyOU43KM7:TR?= NXHvZmlpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewO|czOjhpPkK3NFc4OjJ6PD;hQi=>
Ramos cells Ml3QR5l1d3SxeHnjbZR6KGG|c3H5 NYjN[IV6OjRiaB?= MXrJR|UxKD1iMkiuO{DPxE1? MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ5NE[3OUc,Ojh{N{S2O|U9N2F-

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
pEGFR(Tyr1068) / EGFR; 

PubMed: 28061447     


Ibrutinib inhibitory effects on EGFRY1068 auto-phosphorylation in the HCC827 cell line at different time points by removal of drug after 4 h pretreatment.

pBTK / pPLCγ2 / pAKT / pERK / pJNK; 

PubMed: 23940282     


Mino (left panel) or Jeko1 (right panel) cells pretreated with vehicle or ibrutinib 10, 100, or 1000 nM were either stimulated with anti-IgM, CXCL12, or CXCL13 or treated with medium (Med) for 15 minutes and then immunoblotted for pBTK, pPLCγ2, pAKT, pERK, and pJNK.

28061447 23940282
Immunofluorescence
CD11b; 

PubMed: 30231870     


BV2 microglial cells were pretreated with ibrutinib (1 μM) or vehicle (1% DMSO) for 30 min, followed by treatment with LPS (1 μg/ml) or PBS for 5.5 h and immunostaining with an anti-CD11b antibody. Scale bar = 20 μm.

COX-2; 

PubMed: 30231870     


BV2 microglial cells were treated with vehicle (1% DMSO) or ibrutinib (1 μM) for 30 min, followed by PBS or LPS (1 μg/ml) for 5.5 h, and immunocytochemistry was conducted with anti-CD11b and anti-COX-2 antibodies. 

30231870
ELISA
hTNFα; 

PubMed: 26627823     


PBMs were isolated and pretreated with 1, 5, or 10 μm ibrutinib (IB) or left untreated (UT, −). Pretreated PBMs were incubated for 24 h in 96-well plates precoated without (PBS) or with 10 μg/ml whole human IgG. Cleared supernatants were collected and analyzed by ELISA for TNFα (n = 3).

IL-10; 

PubMed: 27792904     


LMP2A-negative (vector.1/.2) and -positive (express LMP2A) B cell lines were incubated in the absence or presence of increasing concentrations of Ibrutinib for 24 hours and supernatants were isolated for analysis using an IL-10 ELISA.

26627823 27792904
体内試験

In a collagen-induced arthritis model, Ibrutinib significantly reduces clinical arthritis scores reflecting paw swelling and joint inflammation by inhibiting B-cell activation. In a MRL-Fas(lpr) lupus model, Ibrutinib reduces renal disease and autoantibody production. [1] In an adoptive transfer TCL1 mouse model of CLL, Ibrutinib (25 mg/kg/day) causes a transient early lymphocytosis, and delays CLL disease progression. [4]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

- 合併

Kinase Assays :

In vitro kinase IC50 values are measured using 33P filtration binding assay after 1 hour incubation of kinase, 33P-ATP, Ibrutinib, and substrate [0.2 mg/mL poly(EY)(4:1]. Assays are performed at Reaction Biology.
細胞試験:

[2]

- 合併
  • 細胞株: Chronic lymphocytic leukemia (CLL) cells
  • 濃度: 0.01-100 μM
  • 反応時間: 48 hours
  • 実験の流れ:

    MTT (3'[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) assays are performed to determine cytotoxicity. Briefly, cells (CLL B cells or healthy volunteer T cells or NK cells) are incubated for 48 hours with different concentrations of Ibrutinib, or vehicle control. MTT reagent is then added, and plates are incubated for an additional 20 hours before washing with protamine sulfate in phosphate-buffered saline. Dimethyl sulfoxide is added, and absorbance is measured by spectrophotometry at 540 nm in a Labsystems plate reader. Cell viability is also measured at various time points with the use of annexin/PI flow cytometry. Data are analyzed with Expo-ADC32 software package. Results are expressed as the percentage of total positive cells over untreated control. Experiments examining caspase-dependent apoptosis includes the addition of 100μM Z-VAD.


    (参考用のみ)
動物試験:

[1]

- 合併
  • 動物モデル: MRL-Fas(lpr) lupus model and collagen-induced arthritis model.
  • 投薬量: ≤50 mg/kg
  • 投与方法: Administered via p.o.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 88 mg/mL (199.77 mM)
Water Insoluble
Ethanol '45 mg/mL warmed '45
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
5% DMSO+30% PEG 300+5% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 440.5
化学式

C25H24N6O2

CAS No. 936563-96-1
Storage powder
in solvent
別名 N/A
Smiles C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04665115 Withdrawn Drug: Ibrutinib|Other: Quality-of-Life Assessment Asymptomatic COVID-19 Infection Laboratory-Confirmed|B-Cell Neoplasm|Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Small Lymphocytic Lymphoma|Symptomatic COVID-19 Infection Laboratory-Confirmed|Waldenstrom Macroglobulinemia Academic and Community Cancer Research United|National Cancer Institute (NCI) December 2021 Phase 2
NCT05105841 Recruiting Drug: Venetoclax|Drug: Ibrutinib|Drug: Obinutuzumab Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma (SLL) AbbVie November 8 2021 Phase 2
NCT04876092 Recruiting Drug: JNJ-67856633|Drug: Ibrutinib Leukemia Lymphocytic Chronic B-Cell|Lymphoma Non-Hodgkin Janssen Research & Development LLC July 28 2021 Phase 1
NCT04294641 Recruiting Drug: Ibrutinib Chronic GVHD National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) May 10 2021 Phase 2
NCT04514393 Not yet recruiting Drug: Methotrexate|Drug: Ibrutinib|Drug: Temozolomide Primary Central Nervous System Lymphoma|PCNSL|Non Hodgkin Lymphoma Huiqiang Huang|Guangdong 999 Brain Hospital|Nanfang Hospital of Southern Medical University|Xian-Janssen Pharmaceutical Ltd.|Sun Yat-sen University December 1 2020 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    How to reconstitute the compound S2680 for in vivo studies?

  • 回答:

    For in vivo study, we suggest to use 5% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 10mg/ml.

Tags: Ibrutinib (PCI-32765)を買う | Ibrutinib (PCI-32765) ic50 | Ibrutinib (PCI-32765)供給者 | Ibrutinib (PCI-32765)を購入する | Ibrutinib (PCI-32765)費用 | Ibrutinib (PCI-32765)生産者 | オーダーIbrutinib (PCI-32765) | Ibrutinib (PCI-32765)化学構造 | Ibrutinib (PCI-32765)分子量 | Ibrutinib (PCI-32765)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID